info
Google Groups no longer supports new Usenet posts or subscriptions. Historical content remains viewable.
Dismiss
Iron Chelation In Myelodyspastic Syndrome
2 views
Skip to first unread message
ironjustice
Oct 30, 2019, 7:26:30 AM10/30/19
to
Protein Carbonylation in Patients with Myelodysplastic Syndrome: An Opportunity for Deferasirox Therapy.
Rodríguez-García A1, Morales ML2, Garrido-García V3, García-Baquero I4, Leivas A5, Carreño-Tarragona G6, Sánchez R7, Arenas A8, Cedena T9, Ayala RM10, Bautista JM11, Martínez-López J12,13, Linares M14,15.
Antioxidants (Basel). 2019 Oct 24;8(11). pii: E508. doi: 10.3390/antiox8110508.
Abstract
Control of oxidative stress in the bone marrow (BM) is key for maintaining the interplay between self-renewal, proliferation, and differentiation of hematopoietic cells. Breakdown of this regulation can lead to diseases characterized by BM failure such as the myelodysplastic syndromes (MDS). To better understand the role of oxidative stress in MDS development, we compared protein carbonylation as an indicator of oxidative stress in the BM of patients with MDS and control subjects, and also patients with MDS under treatment with the iron chelator deferasirox (DFX). As expected, differences in the pattern of protein carbonylation were observed in BM samples between MDS patients and controls, with an increase in protein carbonylation in the former. Strikingly, patients under DFX treatment had lower levels of protein carbonylation in BM with respect to untreated patients. Proteomic analysis identified four proteins with high carbonylation levels in MDS BM cells. Finally, as oxidative stress-related signaling pathways can modulate the cell cycle through p53, we analyzed the expression of the p53 target gene p21 in BM cells, finding that it was significantly upregulated in patients with MDS and was significantly downregulated after DFX treatment. Overall, our results suggest that the fine-tuning of oxidative stress levels in the BM of patients with MDS might control malignant progression.
KEYWORDS:
carbonylation; deferasirox; myelodysplastic syndromes; oxidative stress
PMID: 31652983 DOI: 10.3390/antiox8110508
Free full text
Who loves ya.
Tom
Jesus Was A Vegetarian!
http://tinyurl.com/2r2nkh
Man Is A Herbivore!
http://tinyurl.com/4rq595
DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk
Rodríguez-García A1, Morales ML2, Garrido-García V3, García-Baquero I4, Leivas A5, Carreño-Tarragona G6, Sánchez R7, Arenas A8, Cedena T9, Ayala RM10, Bautista JM11, Martínez-López J12,13, Linares M14,15.
Antioxidants (Basel). 2019 Oct 24;8(11). pii: E508. doi: 10.3390/antiox8110508.
Abstract
Control of oxidative stress in the bone marrow (BM) is key for maintaining the interplay between self-renewal, proliferation, and differentiation of hematopoietic cells. Breakdown of this regulation can lead to diseases characterized by BM failure such as the myelodysplastic syndromes (MDS). To better understand the role of oxidative stress in MDS development, we compared protein carbonylation as an indicator of oxidative stress in the BM of patients with MDS and control subjects, and also patients with MDS under treatment with the iron chelator deferasirox (DFX). As expected, differences in the pattern of protein carbonylation were observed in BM samples between MDS patients and controls, with an increase in protein carbonylation in the former. Strikingly, patients under DFX treatment had lower levels of protein carbonylation in BM with respect to untreated patients. Proteomic analysis identified four proteins with high carbonylation levels in MDS BM cells. Finally, as oxidative stress-related signaling pathways can modulate the cell cycle through p53, we analyzed the expression of the p53 target gene p21 in BM cells, finding that it was significantly upregulated in patients with MDS and was significantly downregulated after DFX treatment. Overall, our results suggest that the fine-tuning of oxidative stress levels in the BM of patients with MDS might control malignant progression.
KEYWORDS:
carbonylation; deferasirox; myelodysplastic syndromes; oxidative stress
PMID: 31652983 DOI: 10.3390/antiox8110508
Free full text
Who loves ya.
Tom
Jesus Was A Vegetarian!
http://tinyurl.com/2r2nkh
Man Is A Herbivore!
http://tinyurl.com/4rq595
DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk
0 new messages